Global Ultrasound Systems Devices And Equipment Market

The 3D medical imaging market consists of sales of 3D medical imaging equipment and related services. 3D medical imaging is used to create three dimensions’ visual representation of interior body parts for medical analysis with the help of computer-aided design (CAD) or a Magnetic Resonance Image (MRI). The main types in 3D medical imaging are ultrasound, X-ray, CT scan, and others. The x-rays are used to capture images that are 2D and create the illusion of 3D x-ray imaging. The various applications are gynecology and obstetrics, cardiology, neurology, orthopedics, and oncology that are used by various end-users such as diagnostic centers, hospitals, and research centers. The global 3D medical imaging devices market size is expected to decline from $15.99 billion in 2021 to $15.36 billion in 2022 at a compound annual growth rate (CAGR) of -3.9%. The global 3D medical imaging market size is then expected to grow to $19.32 billion in 2026 at a CAGR of 5.9%. Increasing cases of injuries such as sports-related injuries contribute to the growth of the 3D medical imaging market. The increase in sports-related injuries is due to the increasing participation of individuals in organized and unorganized sports activities. Moreover, the training of athletes with high strength and high load also results in more and more serious injuries. Sports injuries are mainly characterized by soft tissue injury. The use of 3D medical imaging devices such as ultrasound diagnosis, X-ray radiography, MRI imaging provides an accurate and objective basis for the diagnosis. The 3D medical imaging devices help in the examination of muscle fascia injury, tendon injury, ligament injury, meniscus injury, articular cartilage, and bone fracture. According to the Centre for the Disease Control and Prevention, it is estimated that there are 775,000 emergency room visits due to the injuries in children who are participating in unorganized and organized sports activities. Thus, the increase in demand for 3D medical imaging devices favors the market growth. The difficulties faced by the medical device industry owing to the COVID-19 outbreak such as the slowdown in orders and supply chain disruptions are likely to restraint the growth of the 3D medical imaging market over the next coming years. According to Medical Products Outsourcing (MPO) magazine published in April 2020, financial strains and supply chain disruptions are the major challenges faced by the medical devices industry. The manufacturers are experiencing a modest slowdown in orders attributed to tight management of inventories due to fear of the spread of the virus and slow pace of reorders owing to the impact of the virus on businesses. Moreover, the managers are also hesitant in overseeing the new product launches in uncertain times. This scenario is predicted to act as a major factor restraining the growth of the market shortly. 3D medical imaging device manufacturers are increasingly investing in Artificial Intelligence (AI) to improve the diagnosis by giving accurate, hard-number measurements. AI provides efficiency in medical imaging, particularly when it comes to detecting organs or anomalies. For instance, by combining image visualization and AI, cardiologists can measure ejection fraction with high precision and in a much shorter period. Ejection fraction is a measurement of the percentage of blood leaving the heart each time it contracts. For instance, In November 2021, GE Healthcare, a company operating in 3D imaging devices unveiled 60 innovative technology solutions including artificial intelligence to transform healthcare to help patients and clinicians with an effective way of solutions. In February 2020, Alphatec Holdings, Inc. (ATEC or the Company) acquired EOS imaging, SA for a purchase price of about $88 million. With this acquisition, ATEC will integrate spine imaging and anatomical modeling for better operative performance and is expected to significantly increase the demand for ATEC hardware and EOS systems. EOS Imaging is a France-based medical device company leading in orthopedic medical imaging solutions. Major players in the 3D medical imaging market are GE Healthcare, Royal Philips, Siemens AG, The Esaote Group, Intrasense SA, Materialize NV, Toshiba Group, Samsung Medison Co Ltd, Shimadzu Corporation, and Analogic Corporation. Western Europe was the largest region in the 3D medical imaging market in 2021. Asia Pacific was the second-largest region in the global 3D medical imaging market. The regions covered in the global 3D medical imaging market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the 3D medical imaging market are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, and USA. The global 3D medical imaging devices market is segmented - 1) By Type: Ultrasound, X-Ray, CT Scan, Others 2) By End-User: Diagnostic Centers, Hospitals, Research Centers 3) By Application: Gynecology and Obstetrics, Cardiology, Neurology, Orthopedics, Oncology

The biopsy devices market consists of sales of biopsy devices and related services by entities (organizations, sole traders, and partnerships) that manufacture biopsy devices. Biopsy devices are used to extract sample cells or tissues from the patient's body to be examined to determine the presence of a disease. The main product types in biopsy devices are needle-based biopsy instruments, core biopsy devices, aspiration biopsy needles, vacuum-assisted biopsy devices, biopsy forceps, and localization wires. The core biopsy devices utilize a large hollow needle to make a small incision in the skin over the lump. The various imaging technologies included are MRI-guided biopsy, stereotactic-guided biopsy, ultrasound-guided biopsy, and CT scan. The applications included in this market are breast biopsy, gynecological biopsy, prostate biopsy, liver biopsy, lung biopsy, kidney biopsy, gastroenterology biopsy, and others that are used in diagnostics and imaging centers, hospitals, and others. The global biopsy devices market size is expected to grow from $2.45 billion in 2021 to $2.64 billion in 2022 at a compound annual growth rate (CAGR) of 8%. The global biopsy device market is expected to grow to $3.54 billion in 2026 at a CAGR of 7.6%. The rise in the number of cancer cases contributed to the growth of the biopsy devices market. A biopsy is a primary approach used by doctors to diagnose any abnormalities in the bodies if the presence of cancer cells is suspected. For instance, in 2020, according to the American Institute of cancer research, there were an estimated 18.1 million cancer cases around the world. It was estimated that 9.3 million cases were in men and 8.8 million in women. Among them, lung and breast cancers are the most common cancers in the world, and about 12.5% and 12.2% of the new cases are diagnosed in 2020. The rise in complications associated with biopsies is expected to limit the growth of the biopsy devices market. Complications resulting from a biopsy include excessive bleeding, infection, puncture damage to nearby organ tissue, and skin numbness around the biopsy site. In some cases, not enough materials are collected and the process needs to be repeated. According to research published in January 2020, major bleeding after percutaneous native kidney biopsy was around 4.3%. These complications in biopsy procedures impact the market's growth. Robot-assisted biopsy systems are shaping the biopsy devices market and help avoid complications after the biopsy. The robot-assisted biopsy is done to increase the precision and accuracy of the biopsy process and medical authorities have been approving the devices to make the process easier. For instance, in 2019, the FDA (Food and Drug Administration) approved Intuitive Surgical Inc’s Ion Endoluminal Lung Biopsy System, a robot-assisted lung biopsy device that uses an ultra-thin articulating robotic catheter. The robotic catheter has an outer diameter of 3.5 mm so that physicians can navigate through thin and tortuous airways and can move 180 degrees in all directions. The system is equipped with a flexible biopsy needle that can pass through tight bends so that it can collect tissue in the peripheral lung. In January 2019, IZI Medical Products, a radiology medical device company, has acquired soft tissue and breast localization needle assets from Cook Medical for an undisclosed amount. The acquisition expands the breadth of the products offered by IZI Medical and strengthens diagnostics and therapeutic areas. Major players in the biopsy devices market are Becton Dickinson and Company (BD), Cook Medical, Argon Medical Devices, Hologic, Boston Scientific Corporation, Cardinal Health, B. Braun Melsungen AG, Medtronic, Devicor Medical Products, and Danaher Corporation (Leica Microsystem). North America was the largest region in the biopsy devices market in 2021. Asia Pacific was the second largest region in the global biopsy device market during the forecast period. The regions covered in the global biopsy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the biopsy devices market are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, and USA. The global biopsy devices market is segmented - 1) By Product Type: Needle-Based Biopsy Instruments, Core Biopsy Devices, Aspiration Biopsy Needles, Vacuum-Assisted Biopsy Devices, Biopsy Forceps, Localization Wires  2) By Imaging Technology: MRI-Guided Biopsy, Stereotactic-Guided Biopsy, Ultrasound-Guided Biopsy, CT Scan 3) By Application: Breast Biopsy, Gynecological Biopsy, Prostate Biopsy, Liver Biopsy, Lung Biopsy, Kidney Biopsy, Gastroenterology Biopsy, Others 4) By End-User: Diagnostics and Imaging Centers, Hospitals, Others

The breast cancer diagnostics market consists of sales of breast cancer diagnostic devices and related services by entities (organizations, sole traders, and partnerships) that produce breast cancer diagnostics devices. These devices are used to diagnose breast cancer. Only goods and services traded between entities or sold to end consumers are included. The main types of breast cancer diagnostics are Imaging, biopsy, genomic tests, blood tests, and others. The biopsy is the process of removing a piece of tissue or a sample of cells from the body so that it can be tested in a laboratory. The technology involved is fluorescent in situ hybridization (FISH), comparative genomic hybridization (CGH), immunohistochemical (IHC), and other technologies. The cancer types involved are brca breast cancer, er & pr breast cancer, her 2-breast cancer, egfr mutation test breast cancer, and others. The diagnostic types involved are ionizing breast imaging technologies and non-ionizing imaging technologies. The end-users involved are hospitals and clinics, cancer research centers, diagnostic laboratories, and ambulatory surgical centers. The global breast cancer diagnostics market size is expected to grow from $3.75 billion in 2021 to $4.06 billion in 2022 at a compound annual growth rate (CAGR) of 8.3%. The global breast cancer diagnostic market is then expected to grow to $5.48 billion in 2026 at a CAGR of 7.8%. The increasing incidence of breast cancer will require more equipment to diagnose, which will further increase the demand for the breast cancer diagnostics market. Breast cancer is the most common form of cancer, affecting 2.1 million women every year, and causing the largest number of deaths from cancer in women. The goal of the early diagnosis is to improve the percentage of breast cancers diagnosed at an initial point so that more successful care will be used and the risk of death from breast cancer can be reduced. According to the World Health Organization (WHO), around 2.3 million women were diagnosed with breast cancer and 685,000 people died of breast cancer in 2020. Therefore, the increasing incidence of breast cancer is expected to drive the growth of the breast cancer diagnostics market. The high cost of diagnosis of breast cancer is a key factor that hinders the growth of the market for diagnostics of breast cancer. The cost of diagnosis for breast cancer typically rose with the initiation of the diagnostic stage of the disease. According to a 2019 study conducted by Mesothelioma Center, around 63% of respondents that comprise of people with cancer and their family members reported financial difficulties. For instance, the total cost of diagnosis for breast cancer was $353 per patient but diagnostic costs varied from $151 in some regions to $751 in others. Therefore, the high-cost diagnosis of breast cancer makes the process a distant option and hinders the growth of the breast cancer diagnostics market. Technological advancement is a key trend in the breast cancer diagnostics market. Several new techniques have been developed which could be used in the diagnosis and treatment of breast cancer. The 3D mammography, also known as breast tomosynthesis, takes photographs around the breast from various angles and translates them into a 3-D model. In March 2019, Southwest Medical Center, a US-based company, launched 3D mammography services that provide patients with access to enhanced breast imaging services closer to home. In November 2019, EXACT Sciences Corporation, a US-based molecular diagnostics company, acquired Genomic Health for $2.8 billion. Through this acquisition, Exact Sciences will be able to facilitate therapy decisions for colorectal, breast, and prostate cancers by Genomic Health’s Oncotype DX gene expression. Genomic Health is a US-based genomic diagnostics manufacturer. Major players in the breast cancer diagnostics market are Abbott Laboratories, Myriad Genetics Inc, Hologic Inc, Koninklijke Philips N.V, Fujifilm Holdings Corporation, GE Healthcare, Thermo Fischer Scientific Inc, Siemens AG, NanoString Technologies Inc, and C. R. Bard Inc. North America was the largest region in the breast cancer diagnostics market in 2021. Asia Pacific was the second largest region in the global breast cancer diagnostics market. The regions covered in the global breast cancer diagnostics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the breast cancer diagnostics market are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The global breast cancer diagnostics market is segmented - 1) By Type: Imaging, Biopsy, Genomic Tests, Blood Tests, Others 2) By Technology: Fluorescent In Situ Hybridization (FISH), Comparative Genomic Hybridization (CGH), Immunohistochemical (IHC), Others 3) By Cancer Type: BRCA Breast Cancer, ER and PR Breast Cancer, HER 2 Breast Cancer, EGFR Mutation Test Breast Cancer, Others 4) By Diagnostic Type: Ionizing Breast Imaging Technologies, Non-Ionizing Imaging Technologies 5) By End-User: Hospitals and Clinics, Cancer Research Centers, Diagnostic Laboratories, Ambulatory Surgical Centers

The interventional radiology market consists of sales of interventional radiology products and related services by entities (organizations, sole traders, and partnerships) that deal with the diagnosis and treatment of patients using minimally invasive image-guided procedures. Interventional radiology is a medical specialty that entails a variety of imaging procedures to get images of the internal organs. These images are carefully interpreted by an interventional radiologist to identify injury and disease, as well as to execute a variety of interventional medical procedures. The market consists of revenue generated by the sales of the company’s manufacturing interventional radiology products and others. The main types of products in the interventional radiology market are MRI, ultrasound imaging, CT scanners, angiography systems, fluoroscopy systems, biopsy devices, and others. MRI interventional radiology devices scan produce detailed images of the organs and tissues in the body. The different procedures include angioplasty, angiography, biopsy and drainage, embolization, thrombolysis, vertebroplasty, nephrostomy, and others and are used in cardiology, urology, nephrology, oncology, gastroenterology, and others. The global interventional radiology market size is expected to grow from $19.07 billion in 2021 to $20.53 billion in 2022 at a compound annual growth rate (CAGR) of 7.6%. The global interventional radiology market is expected to grow to $28.61 billion in 2026 at a CAGR of 8.6%. The increasing prevalence of cancer is expected to drive the growth of the interventional radiology market in the coming years. Cancer is a global health problem and is the second leading cause of death in the United States. Interventional radiology uses a variety of techniques such as ablation, embolization, and irreversible electroporation (IRE) to treat cancer and cardiovascular disorders. For instance, according to the American Cancer Society, there were 1,806,590 new cancer cases and 606,520 cancer deaths in 2020 in the USA. New cases of leukemia, lymphoma, and myeloma are expected to account for 9.9% of the estimated 178,520 new cases diagnosed in the USA in 2020, and in approximately every 3 minutes one person in the US is diagnosed with blood cancer. Hence, the increasing prevalence of cancer drives the growth of the interventional radiology market. The implementation of illumination rendering technology is a key trend gaining popularity in the interventional radiology market. Companies operating in the interventional radiology sector are continuously focusing on introducing new technologies to survive in the interventional radiology market. For instance, in January 2019, Canon medical system corporation, a Japan-based medical equipment company launched illumination rendering technology within its Vitrea platform. This technology allows doctors to interact with photorealistic visuals in real-time and see patient anatomy in three dimensions. The technology will help clinicians and patients understand physiology and pathology, and forensic physicians will be able to visualize anatomy before autopsy reports and use global illumination to facilitate communications. In August 2020, Seimens Healthineers, a Germany-based medical device manufacturer specializing in medical imaging, laboratory diagnostics, point of care diagnostics, and other segments acquired Varian for $16.4 billion. With this acquisition, Seimens plans to expand its cancer devices portfolio used for screening and treating different cancers. Varian is a UK-based medical technology company that provides products for radio-oncology treatments. Major players in the interventional radiology market are Carestream Health, Siemens AG, Koninklijke Philips N.V, General Electric Company, Hitachi Medical Corporation, Canon Medical Systems Corporation, Toshiba Medical Systems, Medtronic plc, Shimadzu Corporation, and Fujifilm Holdings Corp. The regions covered in the global interventional radiology market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the interventional radiology market are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The global interventional radiology market is segmented - 1) By Product: MRI, Ultrasound Imaging, CT Scanners, Angiography Systems, Fluoroscopy Systems, Biopsy Devices, Others 2) By Procedure: Angioplasty, Angiography, Biopsy and Drainage, Embolization, Thrombolysis, Vertebroplasty, Nephrostomy, Others 3) By Application: Oncology, Cardiology, Urology and Nephrology, Gastroenterology, Others

The computed tomography (CT) scanners devices and equipment market consist of sales of computed tomography scanners devices and equipment and related services. CT scanners are used in the diagnosis of various diseases including cancer, bone-related diseases, cardiovascular diseases, gynecological diseases, urological diseases, and other diseases. CT scanners use computer-controlled X-rays to create images of the body. A CT scan is a three-dimensional method of scanning. The main product types in the computed tomography scanners devices and equipment are low slice, medium slice, and high slice. A higher slice CT produces higher resolution images and can produce an image of a heart in a single beat. The various applications involved are oncology, neurology, cardiovascular, musculoskeletal, and others. The end-users involved are clinics, diagnostic services, and hospitals. The global computed tomography (CT) scanners devices and equipment market size is expected to grow from $7.59 billion in 2021 to $8.1 billion in 2022 at a compound annual growth rate (CAGR) of 6.8%. The global CT scanners devices and equipment market size is expected to grow to $9.88 billion in 2026 at a CAGR of 5.1%. The rising prevalence of cancer and cardiovascular diseases is driving the computed tomography scanners devices and equipment market. According to the Centers for Disease Control and Prevention in the USA, the number of new cancer cases will go up by 24% in men and 21% in women by 2020. The rising need for early-stage detection and prevention of these life-threatening diseases, increase the demand for proper diagnostics which poses an opportunity for CT scan manufacturers. For instance, according to the American Heart Association, by 2035, 45.1% of the US population is projected to have some form of CVD. Total costs of CVD are expected to reach $1.1 trillion in 2035, with direct medical costs projected to reach $748.7 billion and indirect costs estimated to reach $368 billion. Effects of radiation and increasing health concerns hinder the computed tomography scanners market growth. Diagnostic imaging procedures use CT scanner devices that release electromagnetic waves or particles called 'ionizing radiation. This radiation coming from manmade sources such as CT scans, nuclear medicine scans, and PET scans carry major health hazards and risks. Low doses can cause cancer in the long run. For instance, according to WHO data 2022, Cancer is a leading cause of death globally, accounting for nearly 10 million deaths in 2020. When doses exceed certain levels it causes skin burns and acute radiation syndrome. According to a global survey conducted by National Council on Radiation Protection and Measurements (NCRP), on radiation overexposure accidents, 2390 people were over-exposed to radiation, out of which 190 died. Companies in the industry are integrating medical imaging with healthcare IT technology by providing digital access to improve patient safety, enhance healthcare facilities and save patients time and money. The data from CT scans are being integrated with an image processing and communicating system such as a picture archiving and communication system (PACS) that brings CT images from multiple systems into one interface. This enables radiologists to securely store, digitally transmit electronic images and clinically-relevant reports, and make use of a comprehensive database of images to give an accurate diagnosis. These are increasingly incorporated and used for clinical analysis, diagnosis, and treatment in departments such as radiology, nuclear medicine imaging, cardiology, pathology, oncology, and dermatology. For example, Carestream Health is a company that makes PACS machines that integrate images from different sources under one interface. An agreement has been signed by Philips to acquire Carestream health in March 2019. Major players in the computed tomography scanner devices and equipment market are GE Healthcare, Koninklijke Philips N.V, Hitachi Ltd, Siemens, Canon Medical Systems Corporation, Neusoft Medical Systems, Hitachi Healthcare America, Neurologica, Samsung Electronics, and Shimadzu Corporation. The regions covered in the global computed tomography scanners market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the global CT scanners market are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, and USA. The global computed tomography (CT) scanners devices and equipment market is segmented - 1) By Product Type: Low Slice, Medium Slice, High Slice 2) By Application: Oncology, Neurology, Cardiovascular, Musculoskeletal, Others 3) By End-User: Clinics, Diagnostic Services, Hospitals

The brain and neuroimaging devices market consists of sales of brain and neuroimaging devices and related services by businesses that manufacture them. Brain and neuroimaging devices are medical devices used to capture the structure and function of the brain for studying the areas affected by neurological disorders, brain functioning, and activity of the brain. The main imaging types of brain and neuroimaging devices are functional magnetic resonance imaging (fMRI), computed tomography (CT), positron emission tomography (PET), electroencephalography (EEG), magnetoencephalography (MEG), and others. Positron emission tomography is a type of imaging technique that measures the metabolic activity of the cells of body tissues using radioactive substances. The various applications of brain and neuroimaging devices are Parkinson's disease, traumatic brain injury, epilepsy, dementia, sleep disorders, and other applications that are used in hospitals, diagnostic centers, and ambulatory surgical centers. The global brain and neuroimaging devices market size is expected to grow from $33.17 billion in 2021 to $35.44 billion in 2022 at a compound annual growth rate (CAGR) of 6.8%. The global brain and neuroimaging device market is expected to grow to $43.84 billion in 2026 at a CAGR of 5.5%. An increase in the incidence of neurological disorders is expected to drive the market. According to a report by Neurological Alliance published in 2019, the number of neurological cases in England has reached 14.7 million and 1 in 6 people suffer from neurological disorders. Brain and neuroimaging devices are used to diagnose neurological disorders increasing the survival rate and management of the disease. This increasing incidence rate is expected to drive the brain and neuroimaging devices market. The high cost of imaging devices is anticipated to hamper the market for brain and neuroimaging devices. Neurological and cognitive psychology research and design brain-computer interfaces require high-end machines such as Electroencephalography (EEG), Positron Emission Tomography (PET), Functional Magnetic Resonance Imaging (fMRI) among others. These are high-cost devices, for instance, the new 64-slice CT scanners range between $500,000 and $700,000, cost of a PETCT scanner ranges from $225,000 to $750,000, which is not affordable for all hospitals and labs, mainly in developing countries. Thus, the high cost of imaging devices hampers the buying capacity of hospitals and diagnostic labs, hampering the brain and neuroimaging devices market. Companies and researchers are focusing on developing portable brain scanners that are expected to revolutionize brain imaging by lowering the cost of devices, making them affordable and accessible to all. EMVision Medical Devices and researchers at Queensland University have developed a portable brain scanner technology that enables brain scanning to be performed at almost any location. Researchers at University College London have developed a portable MEG brain scanner that is lightweight, worn like just a helmet but can measure brain activity even as people make natural movements, providing improved imaging opportunities for patients with disorders that cause unprompted body movements, such as epilepsy. Major players in the brain and neuroimaging devices market are GE, Siemens, Philips, Canon, Hitachi Medical Systems, Medtronic Plc, EB Neuro S.p.A., Neurosoft, MinFound Medical Systems Co Ltd, and Elekta. Western Europe was the largest region in the brain and neuroimaging devices market in 2021. North America was the second largest region in the global brain and neuroimaging devices market during the forecast period. Africa was the smallest region in the brain and neuroimaging devices market. The regions covered in the global brain and neuroimaging market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the brain and neuroimaging devices market are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, and USA. The global brain and neuroimaging devices market is segmented - 1) By Imaging Type: Functional Magnetic Resonance Imaging (fMRI), Computed Tomography (CT), Positron Emission Tomography (PET), Electroencephalography (EEG), Magneto Encephalography (MEG), Others 2) By End-User: Hospitals, Diagnostic Centres, Ambulatory Surgical Centres 3) By Application: Parkinson’s Disease, Traumatic Brain Injury, Epilepsy, Dementia, Sleep Disorders, Others

The 3D diagnostic imaging services market consists of revenues generated by the use of 3D diagnostic imaging procedures such as 3D X-rays, 3D ultrasound, MRI, and other 3D nuclear imaging techniques (PET, SPECT) to diagnose patients with chronic diseases. The 3D diagnostic imaging technique provides advanced services that help in various applications such as oncology, cardiology, orthopedics and others. 3D diagnostic imaging is used to create three dimensional visual representations of interior body parts for medical analysis with the help of Computer-Aided Design (CAD) or a Magnetic Resonance Image (MRI) technology. The main techniques of 3D diagnostic imaging services are ultrasound, MRI, X-ray, computed tomography, others. An ultrasound is a type of imaging test that utilizes sound waves to create images of organs, tissues, and other structures within the body. The various applications include oncology, cardiology, orthopedics, and others that are used by diagnostic centers, hospitals and research centers. The global 3D diagnostic imaging services market size is expected grow from $184.32 billion in 2021 to $195.51 billion in 2022 at a compound annual growth rate (CAGR) of 6.1%. The growth in the 3D diagnostic imaging services market is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The 3D diagnostic imaging services market is expected to reach $246.89 billion in 2026 at a CAGR of 6%. The demand for Point-of-Care Testing (PoCT) has been steadily increasing over the years. The growth in demand is likely to continue and drive the market for 3D diagnostic imaging services market. This is because PoCT allows physicians and medical staff to accurately achieve real-time, lab-quality diagnostic results within minutes rather than hours. Also, the changing healthcare delivery system is aimed at delivering cost effective care at patient’s home. In most of the countries, especially developing countries, more effective care for infectious diseases is needed. PoCT technologies provide effective care with easy-to-use devices and improved analytical performance and recent improvements in the speed, usability and affordability of medical imaging with 3D integration have greatly expanded the capabilities of PoCT testing systems. These advances are greatly driving the 3D diagnostic imaging services market. The 3D diagnostic imaging services market is constrained by the shortage of qualified and skilled healthcare resources. The main reasons are aging workforce, complexity of the latest procedures and their reluctance towards learning the new procedures, and shrinking number of accredited training programs. According to the WHO, there will be a shortage of 18 million health workers by 2030, with the majority of these personnel coming from low- and lower-middle-income countries. The shortage of skilled workforce is expected to affect the 3D diagnostic imaging services market. Therefore, there is an urgent need to train more healthcare professionals in the latest procedures and technologies including 3D imaging to enable accurate diagnosis and treatment in the most efficient manner. Introduction of improved data storage and information sharing systems such as medical cloud technology is creating more growth opportunities for 3D diagnostic imaging. This is because medical imaging requires adequate resources to process, store, exchange and use large quantities of medical data for appropriate diagnostic and treatment decisions, and advanced cloud computing in medical imaging addresses these concerns. Cloud computing is an emerging solution for questions related to delivering complex services and data interchange over the internet. Cloud computing technology enables medical data sharing across regions, allowing more patients to obtain the medical resources they need. It allows easy retrieval of data and provides doctors with more convenient clinical image data services (clear and informative images). Medical cloud imaging has become an important field of cloud computing. In January 2020, Metropolis Healthcare, a chain of diagnostic companies, acquired 51% stake in Shraddha Diagnostic Centre for Rs 9.36 Crores ($1.27 million). This acquisition helps Metropolis Healthcare expand its geographical reach in 9 cities and towns in India. Shraddha Diagnostics is a private company that majorly serves the B2B segment. Major players in the 3D diagnostic imaging services market are Laboratory Corporation of America Holdings, Quest Diagnostics Inc, Alere Inc., Bio-Reference Laboratories, DaVita Healthcare Partners Inc, Genomic Health Inc., Myriad Genetics Inc., NeoGenomics Inc., Sonic Healthcare Limited, Spectra Laboratories and SYNLAB International GMBH. The regions covered in the 3D diagnostic imaging services market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the 3D diagnostic imaging services market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, and USA. The global 3D diagnostic imaging services market is segmented - 1) By Technique: Ultrasound, MRI, X-Ray, Computed Tomography, Others 2) By Application: Oncology, Cardiology, Orthopedic, Others 3) By End User: Diagnostic Centers, Hospitals, Research Centers

The biophotonics market consists of revenues generated from the sales of biophotonic instruments combining optics, nanotechnology, photonics, and biotechnology. Biophotonics is the combination of photonics and biology and is a multidisciplinary research field embracing all light-based technologies applied to life sciences and medicine. It refers to the use of photonic or optical means to examine, control, and track biological processes at various levels of biology: cellular, tissue, molecular, and organism level. The main product technologies in biophotonics are in-vitro and in-vivo. In vitro studies examine microorganisms, cells, and biological molecules outside of their natural biological framework. These studies in biology and its subdisciplines are generally done in labware such as test tubes, flasks, Petri dishes, and microtiter plates, and are referred to as test-tube investigations. The different applications include see-through imaging, inside imaging, spectromolecular, surface imaging, microscopy, light therapy, biosensors, others and are used by various sectors such as diagnostics, therapeutic, tests, others. The global biophotonics market size is expected to grow from $60.45 billion in 2021 to $67.04 billion in 2022 at a compound annual growth rate (CAGR) of 10.9%. The growth in the market is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The biophotonics market is expected to reach $101.57 billion in 2026 at a CAGR of 10.9%. The increasing demand for minimally invasive surgeries is contributing to the growth of the biophotonics market. Optical engineering and imaging technologies are playing a vital role in the evolving field of minimally invasive surgeries by enabling to visualize the manipulation of tissue at remote internal sites. According to the plastic surgery statistics report 2019, the minimally invasive cosmetic procedures reached 16.3 million in 2019, an increase of 2% over the previous year. Therefore, the surge in the number of minimally invasive surgeries annually worldwide is generating higher revenues for the biophotonics market. High prices of biophotonic-based devices or instruments are anticipated to limit the growth of the biophotonics market. The price of biophotonics is comparatively higher than that of conventional instruments. They are considered as more complex attributing to the integration of biological units and the generation, manipulation, and detection of light units, thereby rising their price. This will negatively impact the biophotonics market growth. The launch of new advanced techniques in the field of biotechnology is a major trend shaping the biophotonics market. For instance, a team of scientists at the University of St. Andrews (Scotland) developed a fluorescence microscopy technique that allows imaging of delicate biological samples with low damage in neuroscience and biomedicine. This low damage optical technique is projected to transform the world of biomedicine during the forthcoming years. Hence, the development of new and advanced techniques is gaining significant popularity in the biophotonics market. In April 2021, CellaVision, a Sweden based company that offers digital Morphology Solutions acquired exclusive rights to a patent portfolio on Fourier Ptychographic Microscopy from Clearbridge BioPhotonics for $3.28 million (SEK 28.7 million). Through this acquisition CellaVision will have access to and control over a promising future technology. CellaVision believes that the Fourier Ptychography Microscopy technology has the capability to be employed in the development of future automated microscopes for use in haematology and related fields. Clearbridge Biophotonics, Inc. is a US-based imaging solutions company. Major players in the biophotonics market are Thermo Fisher Scientific, OPGEN, NU Skin Enterprises, IPG Photonics Corp., Idex Corp, Toshiba, Procter & Gamble, Horiba and Precision Photonics Corp. The regions covered in the biophotonics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the biophotonics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The global biophotonics market is segmented - 1) By Product Technology: In-Vitro, In-Vivo 2) By Application: See-Through Imaging, Inside Imaging, Spectromolecular, Surface Imaging, Microscopy, Light Therapy, Biosensors, Others 3) By End Use: Diagnostics, Therapeutic, Tests, Others